Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.
Niethammer AG, Lubenau H, Mikus G, Knebel P, Hohmann N, Leowardi C, Beckhove P, Akhisaroglu M, Ge Y, Springer M, Grenacher L, Buchler MW, Koch M, Weitz J, Haefeli WE, Schmitz-Winnenthal FH. Niethammer AG, et al. Among authors: lubenau h. BMC Cancer. 2012 Aug 20;12:361. doi: 10.1186/1471-2407-12-361. BMC Cancer. 2012. PMID: 22906006 Free PMC article. Clinical Trial.
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.
Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P. Schmitz-Winnenthal FH, et al. Among authors: lubenau h. Oncoimmunology. 2015 Mar 16;4(4):e1001217. doi: 10.1080/2162402X.2014.1001217. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26137397 Free PMC article.
A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.
Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P. Schmitz-Winnenthal FH, et al. Among authors: lubenau h. Oncoimmunology. 2018 Jan 16;7(4):e1303584. doi: 10.1080/2162402X.2017.1303584. eCollection 2018. Oncoimmunology. 2018. PMID: 29632710 Free PMC article.
Profile: VAXIMM.
Breiner K, Lubenau H. Breiner K, et al. Among authors: lubenau h. Hum Vaccin Immunother. 2013 Nov;9(11):2283-4. doi: 10.4161/hv.26479. Epub 2013 Sep 16. Hum Vaccin Immunother. 2013. PMID: 24043272 Free article. No abstract available.
XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.
del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H. del Giglio A, et al. Among authors: lubenau h. BMC Cancer. 2008 Nov 12;8:332. doi: 10.1186/1471-2407-8-332. BMC Cancer. 2008. PMID: 19014494 Free PMC article. Clinical Trial.
XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.
Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A. Gatzemeier U, et al. Among authors: lubenau h. J Thorac Oncol. 2009 Jun;4(6):736-40. doi: 10.1097/JTO.0b013e3181a52964. J Thorac Oncol. 2009. PMID: 19404210 Free article. Clinical Trial.
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A. Engert A, et al. Among authors: lubenau h. Leuk Lymphoma. 2009 Mar;50(3):374-9. doi: 10.1080/10428190902756081. Leuk Lymphoma. 2009. PMID: 19347726 Clinical Trial.